Company / Working Capital
Cytokinetics Working Capital History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital
$714.5M
FY2025
5-year range
$463.8M / $928.3M
FY2021-FY2025
Trend
-23.0%
vs FY2024
Sector context
#62 of 213
Health Care
What the data says
At $715M, Cytokinetics's working capital ranks #62 of 213 in the Health Care sector. Working Capital has fluctuated over the past 10 years, ranging from $125M in FY2016 to $928M in FY2024.
Based on SEC 10-K filings.
$715M in FY2025 with a 5-year CAGR of +10.0%.
Improved from $525M to $715M over the past 2 years.
Health Care sector context is included.
Working Capital over time
Growth rates
- 3-Year CAGR
- +0.2%
- 5-Year CAGR
- +10.0%
- 10-Year CAGR
- -
Sector benchmark
#62 of 213 in Health CareTop 29% of 213This company $714.5M Sector average $934.6M
▼
-23.5% below sector average
Key checks
Key Insights
- 5-year CAGR of +10.0%, indicating consistent growth.
- In FY2025, working capital decreased 23.0% year-over-year.
- Ranks #62 out of 213 companies in the Health Care sector.
- Peak working capital was recorded in FY2024.
Company context
Key Data Points
- Altman Z-Score -3.12 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working CapitalValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $714.5M | -23.0% |
| FY2024 | $928.3M | +76.7% |
| FY2023 | $525.4M | -26.1% |
| FY2022 | $710.6M | +53.2% |
| FY2021 | $463.8M | +4.7% |
| FY2020 | $443.0M | +113.3% |
| FY2019 | $207.7M | +12.0% |
| FY2018 | $185.5M | -23.3% |
| FY2017 | $241.9M | +92.9% |
| FY2016 | $125.4M | +53.9% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026